CurrentCignaPolicy N/A

Parkinson's Disease Duopa Prior Authorization Policy

Defines Cigna's prior authorization requirements and medical necessity criteria for coverage of Duopa for treatment of motor fluctuations in advanced Parkinson's disease for members under Cigna-administered plans.

Policy Summary

PayerCigna

PolicyParkinson's Disease Duopa Prior Authorization Policy

Policy CodePolicy N/A

Change TypeNo material changes

Effective DateN/A

Next Review DateMar 12, 2025

Key ActionObtain prior authorization and document trials including an oral extended‑release carbidopa/levodopa, three other therapies for 'off' episodes, and prescriber neurologist involvement.

SourceLink

POLICY UPDATE CHANGES

No material clinical or coverage changes in this revision.

1 yearapproval duration

3prior therapies required

FDA-approvedindication

NCstate

Coverage Criteria for Duopa

Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.

A) Patient is diagnosed with advanced Parkinson's disease.
B) Patient is experiencing 'off' episodes (examples: muscle stiffness, slow movements, difficulty starting movements).
C) Prior trial of oral extended-release carbidopa/levodopa
- Patient has tried an oral extended-release carbidopa/levodopa therapy and had significant intolerance, according to the prescriber.
- Patient has tried an oral extended-release carbidopa/levodopa therapy and had inadequate efficacy, according to the prescriber.
D) Patient has previously tried THREE other treatments for 'off' episodes (examples include entacapone, rasagiline, pramipexole, ropinirole, tolcapone, cabergoline, selegiline, Ongentys (opicapone), or Xadago (safinamide)).
E) Medication is prescribed by or in consultation with a neurologist.

Approval duration and note

Approval duration = 1 year.
Approve for 1 year if ALL criteria met.

Provider Requirements and Prior Authorization

Prior Authorization

Prior Authorization Required

Prior authorization required — approvals provided for 1 year when criteria met. Because of the specialized skills required for evaluation and diagnosis of patients treated with Duopa, approval requires the medication to be prescribed by or in consultation with a physician who specializes in the condition being treated (neurologist).

Approval duration: 1 year
Prescriber requirement: prescribed by or in consultation with a neurologist

Step Therapy

Step Therapy / Prior Trials

Step therapy: patient must have tried an oral extended‑release carbidopa/levodopa and meet one of: documented significant intolerance to that therapy or inadequate efficacy as determined by the prescriber.

Required prior trial: oral extended‑release carbidopa/levodopa
Acceptable exceptions: prescriber-documented intolerance OR prescriber-determined inadequate efficacy

Documentation Required

Required Clinical Documentation

Documentation must support a diagnosis of advanced Parkinson's disease and evidence of 'off' episodes (examples: muscle stiffness, slow movements, difficulty starting movements). Include documentation of prior therapies tried for 'off' episodes and rationale for why oral extended‑release carbidopa/levodopa was not effective or not tolerated.

Evidence of advanced Parkinson's disease diagnosis
Documentation of 'off' episodes (clinical examples noted)
Record of prior therapies tried for 'off' episodes and outcomes
Documentation of intolerance or inadequate efficacy for oral extended‑release carbidopa/levodopa

Denial Risk

Triggers for Denial

Denial will be issued if the patient does not meet ALL required criteria: not diagnosed with advanced Parkinson's disease; no evidence of 'off' episodes; failure to document required prior trials (including oral extended‑release carbidopa/levodopa) or lack of prescriber justification for exceptions; fewer than three prior treatments for 'off' episodes; or medication not prescribed by/with consultation of a neurologist. Duopa is considered experimental/investigational/unproven for any non‑approved use.

Missing diagnosis of advanced Parkinson's disease
No documented 'off' episodes
No documented trial of oral extended‑release carbidopa/levodopa without documented intolerance or inadequate efficacy
Fewer than three prior treatments for 'off' episodes documented
Not prescribed by or in consultation with a neurologist
Request for unapproved indication (experimental/investigational)

Key Definitions

Off episodes — definition and examples

DefinitionPeriods when Parkinson's symptoms worsen (’off’ episodes).

Common examplesMuscle stiffness; slow movements (bradykinesia); difficulty initiating or starting movements (akinesia).

Clinical contextListed as part of FDA‑approved criteria for Duopa for advanced Parkinson’s disease; documentation of these episodes is required for prior authorization.

Duopa — enteral suspension of carbidopa and levodopa

DefinitionDuopa is an enteral suspension formulation combining carbidopa and levodopa for management of motor fluctuations in advanced Parkinson's disease.

IndicationIndicated for treatment of motor fluctuations (FDA‑approved) in patients with advanced Parkinson's disease.

Prior authorization noteCoverage requires meeting FDA‑approved criteria including diagnosis of advanced Parkinson’s disease, documented ‘off’ episodes, prior trials, and neurologist prescribing/consultation.

Background

Duopa is an enteral suspension formulation of carbidopa and levodopa indicated for the treatment of motor fluctuations in patients with advanced Parkinson’s disease. It is used in patients experiencing “off” episodes — periods when Parkinson’s symptoms worsen, such as muscle stiffness, slow movements, or difficulty initiating movements — and may be considered when patients have inadequate response or intolerance to oral therapies and meet prior authorization criteria. Clinical guidance recognizes Duopa as an efficacious option for managing motor fluctuations in this population.